(secondQuint)Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer.

 This is a single arm, phase 2 study of neoadjuvant triplet chemotherapy regimen of oxaliplatin, irinotecan combined with 5-fluorouraci/leucovorin or S-1 or capecitabine in patients with resectable colorectal cancer.

Fifty patients will be enrolled in this trial.

 The primary objective of this study is to determine the 3-year disease-free survival of the patients.

.

 Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer@highlight

Colorectal cancer is an aggressive malignancy with a poor overall outcome.

 The purpose of this study is to evaluate the feasibility, safety and efficacy of neoadjuvant oxaliplatin, irinotecan combined with 5-fluorouraci/leucovorin or S-1 or capecitabine in patients with resectable colorectal cancer.

